Zebranie naukowe 27.04.2026 – mgr Aleksandra Bober

Mechanisms of pain hypersensitivity in metabolic diseases: the role of CCR2, CCR5 and MC4R

Literatura:

1. Bober A, Piotrowska A, Pawlik K, et al. A New Application for Cenicriviroc, a Dual CCR2/CCR5 Antagonist, in the Treatment of Painful Diabetic Neuropathy in a Mouse Model. Int J Mol Sci. 2024;25(13):7410. Published 2024 Jul 5. doi:10.3390/ijms25137410
2. Bober A, Mika J, Piotrowska A. A Missing Puzzle in Preclinical Studies-Are CCR2, CCR5, and Their Ligands’ Roles Similar in Obesity-Induced Hypersensitivity and Diabetic Neuropathy?-Evidence from Rodent Models and Clinical Studies. Int J Mol Sci. 2024;25(20):11323. Published 2024 Oct 21. doi:10.3390/ijms252011323
3. Starowicz K, Mousa SA, Obara I, et al. Peripheral antinociceptive effects of MC4 receptor antagonists in a rat model of neuropathic pain – a biochemical and behavioral study. Pharmacol Rep. 2009;61(6):1086-1095. doi:10.1016/s1734-1140(09)70171-9
4. Starnowska-Sokół J, Piotrowska A, Bogacka J, et al. Novel hybrid compounds, opioid agonist+melanocortin 4 receptor antagonist, as efficient analgesics in mouse chronic constriction injury model of neuropathic pain. Neuropharmacology. 2020;178:108232. doi:10.1016/j.neuropharm.2020.108232
5. Piotrowska A, Starnowska-Sokół J, Makuch W, et al. Novel bifunctional hybrid compounds designed to enhance the effects of opioids and antagonize the pronociceptive effects of nonopioid peptides as potent analgesics in a rat model of neuropathic pain. Pain. 2021;162(2):432-445. doi:10.1097/j.pain.0000000000002045